PTC Therapeutics Inc. (PTCT)

43.08
0.11 0.26
NASDAQ : Health Technology
Prev Close 42.97
Open 42.70
Day Low/High 42.28 / 43.33
52 Wk Low/High 27.53 / 48.99
Volume 55.76K
Avg Volume 458.70K
Exchange NASDAQ
Shares Outstanding 58.95M
Market Cap 2.54B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Biotech Premarket Movers: Aurinia, Puma, PTC, Juno

Aurinia Pharmaceuticals, Puma Biotechnology, PTC Therapeutics and Juno Therapeutics were among the biotech stock movers in premarket trading on Thursday.

PTC Therapeutics Suffers Cystic Fibrosis Setback, Dimming Hopes for Any U.S. Approvals

PTC Therapeutics Suffers Cystic Fibrosis Setback, Dimming Hopes for Any U.S. Approvals

The latest setback occurred in a phase III study of cystic fibrosis patients, where treatment with ataluren over 48 weeks failed to improve lung function compared to a placebo.

Noteworthy Friday Option Activity: PTCT, UVV, SREV

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 6,944 contracts has been traded thus far today, a contract volume which is representative of approximately 694,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 101.6% of PTCT's average daily trading volume over the past month, of 683,330 shares.

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

Sarepta Opens Up About Duchenne Drug Launch, Allays Investors' Worst Fears

There are 250 Duchenne patients starting the process to receive reimbursement and treatment with Exondys 51, Sarepta says.

PTCT Crosses Above Average Analyst Target

PTCT Crosses Above Average Analyst Target

In recent trading, shares of PTC Therapeutics Inc have crossed above the average analyst 12-month target price of $14.17, changing hands for $14.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Notable Thursday Option Activity: PTCT, HAIN, MRTX

Notable Thursday Option Activity: PTCT, HAIN, MRTX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PTC Therapeutics Inc , where a total of 3,841 contracts have traded so far, representing approximately 384,100 underlying shares. That amounts to about 56.6% of PTCT's average daily trading volume over the past month of 678,305 shares.

Commit To Purchase PTC Therapeutics At $8, Earn 23.8% Using Options

Commit To Purchase PTC Therapeutics At $8, Earn 23.8% Using Options

Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $11.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.90.

PTC Therapeutics Duchenne Drug Wins Extended European Approval

PTC Therapeutics Duchenne Drug Wins Extended European Approval

The news that Translarna will remain on the European market for at least five more years sent PTC Therapeutics shares soaring.

Bullish and Bearish Reversals for the Week

Bullish and Bearish Reversals for the Week

Materials, financials, cyclicals and health care names tilt the scale to the bullish side.

RSI Alert: PTC Therapeutics (PTCT) Now Oversold

RSI Alert: PTC Therapeutics (PTCT) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.

Commit To Purchase PTC Therapeutics At $5, Earn 22% Using Options

Commit To Purchase PTC Therapeutics At $5, Earn 22% Using Options

Investors considering a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $10.24/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.10.

10 Best-Performing Stocks This Earnings Season

10 Best-Performing Stocks This Earnings Season

Which stocks have had the highest gains following earnings? Bespoke Investment came up with a list of the 40 stocks that had the best performance on their earnings reaction days.

Today's Perilous Reversal Stock: PTC Therapeutics (PTCT)

Today's Perilous Reversal Stock: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Volume: PTC Therapeutics (PTCT)

Strong On High Volume: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

European regulators have delayed PTC Therapeutics' request for permanent approval of its Duchenne muscular dystrophy drug Translarna.

Strong On High Relative Volume: PTC Therapeutics (PTCT)

Strong On High Relative Volume: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a strong on high relative volume candidate

Commit To Purchase PTC Therapeutics At $5, Earn 30% Using Options

Commit To Purchase PTC Therapeutics At $5, Earn 30% Using Options

Investors considering a purchase of PTC Therapeutics Inc shares, but tentative about paying the going market price of $6.65/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $5 strike, which has a bid at the time of this writing of $1.50.

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

PTC Therapeutics (PTCT) Weak On High Volume

PTC Therapeutics (PTCT) Weak On High Volume

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a weak on high relative volume candidate

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

GPM Reminds Investors Of The May 2 Deadline In The Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors To Contact The Firm

GPM Reminds Investors Of The May 2 Deadline In The Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming May 2, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased PTC Therapeutics, Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of PTC Therapeutics, Inc.

EXPANDED CLASS PERIOD: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm

EXPANDED CLASS PERIOD: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against PTC Therapeutics, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces that a class action lawsuit has been filed against PTC Therapeutics, Inc.

INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Class Action Involving PTC Therapeutics, Inc. And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT

INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of Class Action Involving PTC Therapeutics, Inc. And A Lead Plaintiff Deadline Of May 2, 2016 - PTCT

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PTC Therapeutics, Inc.

Today's Dead Cat Bounce Stock Is PTC Therapeutics (PTCT)

Today's Dead Cat Bounce Stock Is PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate

Perilous Reversal Stock: PTC Therapeutics (PTCT)

Perilous Reversal Stock: PTC Therapeutics (PTCT)

Trade-Ideas LLC identified PTC Therapeutics (PTCT) as a "perilous reversal" (up big yesterday but down big today) candidate

Why PTC Therapeutics (PTCT) Stock Is Spiking Today

Why PTC Therapeutics (PTCT) Stock Is Spiking Today

PTC Therapeutics (PTCT) stock is skyrocketing this afternoon after a U.K. regulator recommended its drug for a deadly muscle disease.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of PTC Therapeutics, Inc. Of Class Action Lawsuit And A Lead Plaintiff Deadline Of May 2, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of PTC Therapeutics, Inc.

TheStreet Quant Rating: D (Sell)